Cochrane · systematic review · CD002827

Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies

Lunn, MPT, Nobile‐Orazio, E · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library

Neuromuscular2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 2 · 33.3%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Rituximab versus placebo for treating IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathy

Population: people with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
6 questions
OutcomeEffectEvidenceStatus / GRADE
Number of participants improved in disability
Rituximab vs placebo
RR 3.51 [1.3, 9.45]2 studies · 73 participantsLow
Downgraded: imprecision
Mean improvement in disability
Rituximab vs placebo
no estimate extracted2 studies · 73 participantsLow
Downgraded: imprecision
Improvement in 10‐metre walk time at 8 to 12 months1
Rituximab vs placebo
no estimate extracted2 studies · 68 participantsModerate
Downgraded: imprecision
Participant subjective impression of change stable or improved at 8 to 12 months
Rituximab vs placebo
RR 1.86 [1.27, 2.71]2 studies · 70 participantsLow
Downgraded: imprecision, indirectness
Change in serum IgM paraprotein concentration 8 months after treatment1
Rituximab vs placebo
no estimate extracted1 study · 26 participantsModerate
Downgraded: imprecision
Any adverse event
Rituximab vs placebo
RR 1.18 [0.84, 1.66]2 studies · 80 participantsVery low
Downgraded: imprecision, inconsistency